Company intelligence / Profile preview

Beijing Sunbio Biotech

Beijing, Beijing, Chinasunbio.com ↗

Ownership: Private
Development stage: Commercial

Overview

Beijing Sunbio Biotech developed aponermin, a circularly permuted recombinant human TRAIL protein, which acts as an agonist for TRAIL receptors. Aponermin has been registered and received first global approval in China for the treatment of multiple myeloma as part of combination therapy for patients who have received at least one prior line of therapy. As of February 2025, a phase II clinical trial is ongoing in China. No active development is reported for solid tumors at this time.

Therapeutic areas: Oncology
Modalities: Recombinant proteinImmunotherapyAntineoplastic agent
Industry: Biotech

Drug pipeline

1 asset

aponermin

Beyond the preview

Go deeper on Beijing Sunbio Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beijing Sunbio Biotech.

Explore the full profile